Search

GA in Practice Background

Editorial Feature:

GA in Practice

How data and personal experience are evolving the treatment of geographic atrophy.

Why Retina Specialists Are Growing More Comfortable With Early Treatment

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Show Description +

What does treating geographic atrophy earlier actually look like in practice? Moderator Geeta Lalwani, MD, and panelists Murtaza Adam, MD, and Carl Danzig, MD, weigh how factors such as fellow-eye status, lesion growth over time, and patient age shape their treatment decisions in patients with early GA, and they make the case for why dosing interval and patient motivation matter just as much as imaging biomarkers.

Posted: 7/01/2026

Keywords:

early treatment

•

Geographic Atrophy (GA)

•

complement

•

fellow eye

•

Lesions

•

treatment decision

•

dosing

•

interval

•

Diagnostics/Imaging

•

Biomarkers

Up Next

Talking to Patients About Treatment Risks

Talking to Patients About Treatment Risks

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

GA in the Presence of Dense Cataract, Followed by CNV Development

GA in the Presence of Dense Cataract, Followed by CNV Development

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Delayed Complement Inhibition Therapy per Patient Request

Delayed Complement Inhibition Therapy per Patient Request

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

GA Patient Who Becomes Monocular Over Time Due to the Wet AMD

GA Patient Who Becomes Monocular Over Time Due to the Wet AMD

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Complement Inhibition Therapy in a Monocular Patient With a New CNV

Complement Inhibition Therapy in a Monocular Patient With a New CNV

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Multimodal Imaging for Biomarker Detection in GA Patients

Multimodal Imaging for Biomarker Detection in GA Patients

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

Back to All Videos

Why Retina Specialists Are Growing More Comfortable With Early Treatment

Geeta Lalwani, MD; Murtaza Adam, MD; and Carl Danzig, MD

What does treating geographic atrophy earlier actually look like in practice? Moderator Geeta Lalwani, MD, and panelists Murtaza Adam, MD, and Carl Danzig, MD, weigh how factors such as fellow-eye status, lesion growth over time, and patient age shape their treatment decisions in patients with early GA, and they make the case for why dosing interval and patient motivation matter just as much as imaging biomarkers.

Posted: 7/01/2026

Keywords:

early treatment

•

Geographic Atrophy (GA)

•

complement

•

fellow eye

•

Lesions

•

treatment decision

•

dosing

•

interval

•

Diagnostics/Imaging

•

Biomarkers

Please log in to leave a comment.